How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, discovers, develops, manufactures, and delivers human therapeutics. With a market cap of $156.1 billion, the company focuses on human therapeutics and concentrates on innovating novel medicines based on cellular and molecular biology.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and AMGN perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the general drug manufacturers industry. AMGN has a diverse and innovative product portfolio, including blockbuster drugs like Prolia, ENBREL, and XGEVA. Amgen's robust pipeline features potential first-in-class medicines. With operations worldwide, Amgen has established a strong market presence and international sales growth, diversifying revenue and mitigating market-specific risks.